Rule 2.7, 3.10.3, 3.10.4, 3.10.5

Appendix 3B

New issue announcement, application for quotation of additional securities and agreement

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

 $Introduced o1/07/96 \ \ Origin: Appendix 5 \ \ Amended o1/07/98, o1/09/99, o1/07/00, 30/09/01, 11/03/02, o1/01/03, 24/10/05, o1/08/12, o4/03/13$

Name of entity			

ABN

37 063 259 754

We (the entity) give ASX the following information.

Part 1 - All issues

Novogen Limited ("Novogen")

You must complete the relevant sections (attach sheets if there is not enough space).

⁺Class of ⁺securities issued or to be issued

Fully paid ordinary share (Share)

- Number of *securities issued or to be issued (if known) or maximum number which may be issued
- A. 1,967,131
- B. 1,567,240
- C. 2,211,274

Total = 5,745,645 Shares

Principal terms of the 3 if options, +securities (e.g. exercise price and expiry date; if partly paid *securities, the amount outstanding and due dates for payment; if +convertible securities, the conversion price and dates for conversion)

Fully-paid ordinary voting shares Ranks pari passu with all existing Ordinary Shares

⁺ See chapter 19 for defined terms.

Do the *securities rank equally All the shares referred to in item 2 will rank 4 in all respects from the +issue pari passu with all existing Ordinary Shares date with an existing +class of quoted +securities? If the additional *securities do not rank equally, please state: • the date from which they do the extent to which they participate for the next dividend, (in the case of a trust, distribution) interest payment the extent to which they do not rank equally, other than in relation to the next dividend, distribution or interest payment Issue price or consideration \$0.150 5 В. \$0.125 C. \$0.125 6 Purpose of the issue The Shares referred to in the item 2 are issued (If issued as consideration for pursuant to the exercise of unlisted options. Funds the acquisition of assets, clearly will be used for continued research. identify those assets) 6a Is the entity an +eligible entity that has obtained security holder approval under rule 7.1A? If Yes, complete sections 6b - 6h in relation to the +securities the subject of this Appendix 3B, and comply with section 6i 6b The date the security holder 12 November 2014 resolution under rule 7.1A was passed 6c Number of *securities issued N/A without security holder approval under rule 7.1

Appendix 3B Page 2 04/03/2013

⁺ See chapter 19 for defined terms.

6d	Number of *securities issued with security holder approval under rule 7.1A	N/A
6e	Number of *securities issued with security holder approval under rule 7.3, or another specific security holder approval (specify date of meeting)	5,745,645
6f	Number of *securities issued under an exception in rule 7.2	N/A
6g	If *securities issued under rule 7.1A, was issue price at least 75% of 15 day VWAP as calculated under rule 7.1A.3? Include the *issue date and both values. Include the source of the VWAP calculation.	N/A
6h	If *securities were issued under rule 7.1A for non-cash consideration, state date on which valuation of consideration was released to ASX Market Announcements	N/A
6i	Calculate the entity's remaining issue capacity under rule 7.1 and rule 7.1A – complete Annexure 1 and release to ASX Market Announcements	Listing Rule 7.1: 43,816,091 Listing Rule 7.1A: 10,449,603 Total = 54,265,964
7	*Issue dates Note: The issue date may be prescribed by ASX (refer to the definition of issue date in rule 19.12). For example, the issue date for a pro rata entitlement issue must comply with the applicable timetable in Appendix 7A. Cross reference: item 23 of Appendix 2B.	A. 23 April 2015B. 24 April 2015C. 27 April 2015
	Cross reference: item 33 of Appendix 3B.	
8	Number and +class of all +securities quoted on ASX (including the +securities in section 2 if applicable)	Number +Class 292,107,271 Ordinary Shares

⁺ See chapter 19 for defined terms.

9 Number and *class of all *securities not quoted on ASX (including the *securities in section 2 if applicable)

Number	+Class
11,655,472	Unlisted options with exercise price of \$0.125 and expiry date of
9 466 470	18/11/2015.
8,466,470	Unlisted options with exercise price of \$0.15 and expiry date of 16/12/2019.
7,439,938	Unlisted options with exercise price of \$0.15 and expiry date of 18/12/2019.
60,000,000	Unlisted convertible notes, with face values of \$1,500,000

Dividend policy (in the case of a trust, distribution policy) on the increased capital (interests)

N/A			

Part 2 - Pro rata issue

11	Is security holder approval required?	
12	Is the issue renounceable or non-renounceable?	
13	Ratio in which the *securities will be offered	
14	⁺ Class of ⁺ securities to which the offer relates	
15	⁺ Record date to determine entitlements	
16	Will holdings on different registers (or subregisters) be aggregated for calculating entitlements?	
17	Policy for deciding entitlements in relation to fractions	

Appendix 3B Page 4 04/03/2013

⁺ See chapter 19 for defined terms.

18	Names of countries in which the entity has security holders who will not be sent new offer documents
	Note: Security holders must be told how their entitlements are to be dealt with.
	Cross reference: rule 7.7.
10	Closing date for receipt of
19	Closing date for receipt of acceptances or renunciations

⁺ See chapter 19 for defined terms.

Appendix 3B New issue announcement

20	Names of any underwriters	
21	Amount of any underwriting fee	
	or commission	
22	Names of any brokers to the issue	
	issue	
23	Fee or commission payable to the	
	broker to the issue	
	A	
24	Amount of any handling fee payable to brokers who lodge	
	acceptances or renunciations on	
	behalf of security holders	
25	If the issue is contingent on	
	security holders' approval, the	
	date of the meeting	
26	Date entitlement and acceptance	
20	form and offer documents will be	
	sent to persons entitled	
27	If the entity has issued options,	
	and the terms entitle option holders to participate on	
	exercise, the date on which	
	notices will be sent to option	
	holders	
	5	
28	Date rights trading will begin (if applicable)	
	applicable)	
29	Date rights trading will end (if	
,	applicable)	
20	How do goggier boldone sell	
30	How do security holders sell their entitlements <i>in full</i> through	
	a broker?	
31	How do security holders sell part	
	of their entitlements through a	
	broker and accept for the balance?	
	Daidlice:	

Appendix 3B Page 6 04/03/2013

⁺ See chapter 19 for defined terms.

32	of the	do security holders dispose eir entitlements (except by hrough a broker)?	
33	⁺ Issue	e date	
		uotation of securitie	S oplying for quotation of securities
34	Type (tick o	of ⁺ securities one)	
(a)	X	⁺ Securities described in Part	1
(b)		. *	nd of the escrowed period, partly paid securities that become fully paid, en restriction ends, securities issued on expiry or conversion of convertible
Entitie	es tha	t have ticked box 34(a)	
Addit	ional	securities forming a nev	v class of securities
Tick to docume		e you are providing the informat	ion or
35			securities, the names of the 20 largest holders of the he number and percentage of additional *securities
36			r securities, a distribution schedule of the additional amber of holders in the categories
37		A copy of any trust deed for	the additional ⁺ securities

⁺ See chapter 19 for defined terms.

Entitie	Entities that have ticked box 34(b)			
38	Number of *securities for which *quotation is sought			
39	⁺ Class of ⁺ securities for which quotation is sought			
40	Do the *securities rank equally in all respects from the *issue date with an existing *class of quoted *securities? If the additional *securities do not rank equally, please state: • the date from which they do • the extent to which they participate for the next dividend, (in the case of a trust, distribution) or interest payment • the extent to which they do not rank equally, other than in relation to the next dividend, distribution or interest payment			
41	Reason for request for quotation now Example: In the case of restricted securities, end of restriction period (if issued upon conversion of another *security, clearly identify that other *security)			
42	Number and +class of all +securities quoted on ASX (including the +securities in clause 38)	Number	⁺ Class	

Appendix 3B Page 8 04/03/2013

⁺ See chapter 19 for defined terms.

Quotation agreement

- [†]Quotation of our additional [†]securities is in ASX's absolute discretion. ASX may quote the [†]securities on any conditions it decides.
- 2 We warrant the following to ASX.
 - The issue of the *securities to be quoted complies with the law and is not for an illegal purpose.
 - There is no reason why those *securities should not be granted *quotation.
 - An offer of the *securities for sale within 12 months after their issue will not require disclosure under section 707(3) or section 1012C(6) of the Corporations Act.

Note: An entity may need to obtain appropriate warranties from subscribers for the securities in order to be able to give this warranty

- Section 724 or section 1016E of the Corporations Act does not apply to any applications received by us in relation to any *securities to be quoted and that no-one has any right to return any *securities to be quoted under sections 737, 738 or 1016F of the Corporations Act at the time that we request that the *securities be quoted.
- If we are a trust, we warrant that no person has the right to return the *securities to be quoted under section 1019B of the Corporations Act at the time that we request that the *securities be quoted.
- We will indemnify ASX to the fullest extent permitted by law in respect of any claim, action or expense arising from or connected with any breach of the warranties in this agreement.
- We give ASX the information and documents required by this form. If any information or document is not available now, we will give it to ASX before 'quotation of the 'securities begins. We acknowledge that ASX is relying on the information and documents. We warrant that they are (will be) true and complete.

Sign here:Date:27/04/2015......

(Director/Company secretary)

Print name:Lionel Mateo......

== == == ==

⁺ See chapter 19 for defined terms.

Appendix 3B Page 10 04/03/2013

⁺ See chapter 19 for defined terms.

Appendix 3B – Annexure 1

Calculation of placement capacity under rule 7.1 and rule 7.1A for eligible entities

Introduced 01/08/12 Amended 04/03/13

Part 1

Rule 7.1 – Issues exceeding 15% of capital			
Step 1: Calculate "A", the base figurescapacity is calculated	Step 1: Calculate "A", the base figure from which the placement capacity is calculated		
Insert number of fully paid +ordinary securities on issue 12 months before the +issue date or date of agreement to issue	168,557,834		
 Number of fully paid +ordinary securities issued in that 12 month period under an exception in rule 7.2 Number of fully paid +ordinary securities issued in that 12 month period with shareholder approval Number of partly paid +ordinary securities that became fully paid in that 12 month period Note: Include only ordinary securities here – other classes of equity securities cannot be added Include here (if applicable) the securities the subject of the Appendix 3B to which this form is annexed It may be useful to set out issues of securities on different dates as separate line items Subtract the number of fully paid +ordinary securities cancelled during that 12 month period 	123,549,437		
"A"	292,107,271		

⁺ See chapter 19 for defined terms.

Step 2: Calculate 15% of "A"			
"B"	0.15		
	[Note: this value cannot be changed]		
Multiply "A" by 0.15	43,816,091		
Step 3: Calculate "C", the amount of placement capacity under rule 7.1 that has already been used			
Insert number of *equity securities issued or agreed to be issued in that 12 month period not counting those issued:	All previous issue of securities were approved by shareholders at General Meeting held 4 March 2015.		
• Under an exception in rule 7.2			
Under rule 7.1A			
 With security holder approval under rule 7.1 or rule 7.4 			
 Note: This applies to equity securities, unless specifically excluded – not just ordinary securities Include here (if applicable) the securities the subject of the Appendix 3B to which this form is annexed It may be useful to set out issues of securities on different dates as separate line items 			
"C"	0		
Step 4: Subtract "C" from ["A" x "L placement capacity under rule 7.1	B"] to calculate remaining		
"A" x 0.15	43,816,091		
Note: number must be same as shown in Step 2			
Subtract "C"	0		
Note: number must be same as shown in Step 3			
Total ["A" x 0.15] – "C"	43,816,091		
	[Note: this is the remaining placement capacity under rule 7.1]		

Appendix 3B Page 12 04/03/2013

⁺ See chapter 19 for defined terms.

Part 2

Rule 7.1A – Additional placement capacity for eligible entities		
Step 1: Calculate "A", the base figure from which the placement capacity is calculated		
"A"	292,107,271	
Note: number must be same as shown in Step 1 of Part 1		
Step 2: Calculate 10% of "A"		
"D"	0.10	
	Note: this value cannot be changed	
Multiply "A" by 0.10 29,210,727		
Step 3: Calculate "E", the amount of placement capacity under rule 7.1A that has already been used		
 Insert number of †equity securities issued or agreed to be issued in that 12 month period under rule 7.1A Notes: This applies to equity securities – not just ordinary securities Include here – if applicable – the securities the subject of the Appendix 3B to which this form is annexed Do not include equity securities issued under rule 7.1 (they must be dealt with in Part 1), or for which specific security holder approval has been obtained It may be useful to set out issues of securities on different dates as separate line items 	Securities issued on 19/12/2014.	
"E"	18,761,124	

⁺ See chapter 19 for defined terms.

Step 4: Subtract "E" from ["A" x "D"] to calculate remaining placement capacity under rule 7.1A	
"A" x 0.10	29,210,727
Note: number must be same as shown in Step 2	
Subtract "E"	18,761,124
Note: number must be same as shown in Step 3	
Total ["A" x 0.10] – "E"	10,449,603
	Note: this is the remaining placement capacity under rule 7.1A

Appendix 3B Page 14 04/03/2013

⁺ See chapter 19 for defined terms.